Claus-Michael Lehr

Helmholtz Centre for Infection Research

Claus-Michael Lehr is Professor at Saarland University as well as cofounder and head of the department ìDrug Deliveryî at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), which was established as a branch of the Helmholtz Centre for Infection Research (HZI) Braunschweig in 2009. The Helmholtz Association of German Research Centers is the largest public research organization in Germany. In 2015, the HIPS moved into a new state-of-the-art research building. Prof. Lehr has also been cofounder of Across Barriers GmbH and of PharmBioTec GmbH, localized on the same campus of Saarland University in Saarbr¸cken with separate facilities and offering contract research services to pharmaceutical and related companies. The research theme of Prof. Lehr's team is non-invasive drug delivery across biological barriers, in particular the epithelia of the gastrointestinal tract, the skin and the lungs. According to HZIís infection research program, this concept has been expanded to microbial barriers, such as the bacterial cellular envelope, biofilms and host cell membranes. A substantial part of the labís activities is dedicated to innovative carrier systems, often based on nanotechnology, capable of safely and efficiently delivering drugs and vaccines across the barriers. Another part of the efforts is dedicated to human cell and tissue models to evaluate the safety and efficacy of novel therapeutic concepts as alternative to animal testing and to facilitate the translation of new medicines into the clinic. Prof. Lehr is (co)author of more than 380 papers with >15.000 citations (h?index = 68). He is co?editor of the European Journal of Pharmaceutics and Biopharmaceutics and has been the initiator of the biannual International Conference and Workshop ìBiological Barriersî, which has recently taken place at Saarland University in August 2018 for the 12th time. In the same year, the British magazine ìThe Medicine Makerî rated Professor Lehr, for the third time in sequence, as one of the top 100 most influencing drug researchers in the world.

Sessions